Clinical trials: Treatment Resistant Major Depressive Disorder
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Depression, Neurofeedback
Neurofeedback In Treatment Resistant Depression
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04078438
- Testing
- neurofeedback augmentation, treatment as usual
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yeungnam University Hospital
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Major Depressive Disorder, Treatment Resistant Depression
The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression
Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and…
- Trial name
- NCT06163625
- Testing
- Repetitive Transcranial Magnetic Stimulation, Research Interview, Questionnaires, Brain Scan
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment…
- Trial name
- NCT01031810
- Testing
- tranylcypromine
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression, Depression - Major Depressive Disorder
Characterizing Synaptic Density in Treatment Resistant Depression
The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments.
- Trial name
- TPET (NCT03537794)
- Testing
- PET scans
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Major Depression
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET
This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A.
- Trial name
- NCT02379767
- Testing
- Electroconvulsive therapy, Positron emission tomography of the brain using [11C]harmine, Structural magnetic resonance imaging
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression Moderate, Major Depression Severe
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07740694
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Major Depressive Disorder
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.
- Trial name
- NCT04239963
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as…
- Trial name
- NCT02994433
- Testing
- Nitrous Oxide, MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Depression is the leading cause of disability worldwide and around 800,000 suicides occur each year. According to the World Health Organization, major depressive disorder (MDD) is expected to be the leading cause of the global…
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Sham-controlled
- Trial name
- NCT06783361
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ataturk University